News

cobbs_charles_featured

Nativis Appoints Dr. Charles Cobbs as Chairman of Scientific and Medical Advisory Board

cobbs-charles-md-6-1Seattle, Washington (September 29, 2016)Nativis, Inc., a clinical stage life science, bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that Charles Cobbs, M.D., a member of the company’s Scientific and Medical Advisory Board, will expand his role to Chairman.

“Nativis has tremendous potential to transform our approach to treating cancers such as recurrent glioblastoma multiforme (rGBM) using its proprietary ulRFE™ technology,” stated Dr. Cobbs. “I am excited to take a more active role in advising Nativis as the company further develops its platform. I believe that my extensive research in cancer and other serious diseases will be of great value to the development of the Nativis Voyager® system.”

“We are pleased to have Dr. Cobbs chair our Scientific and Medical Advisory Boards as we seek to refine our technology,” commented Chris Rivera, Nativis’ CEO. “His unique blend of research and surgical experience will provide us with valuable insight as we develop our future clinical studies for the Voyager platform for the treatment of rGBM and explore opportunities in other cancers as well as in inflammatory disease and chronic pain indications.”

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.

Media Contact:

Nandi (Thorn) Butcher
nbutcher@feareygroup.com
206.343.1543

Investor Relations Contact:

Lee Roth / Tram Bui
lroth@theruthgroup.com / tbui@theruthgroup.com
646-536-7012 / 7035

Back to News